Montana Passes Significant Health Policy Changes in Controversial Session
The recently ended legislative session was marked by Medicaid reimbursement hikes, abortion restrictions, anti-LGBTQ+ statutes, behavioral health spending, and workforce and insurance measures.
KFF Health News' 'What the Health?': Health Programs Are at Risk as Debt Ceiling Cave-In Looms
A warning from the Treasury Department that the U.S. could default on its debt as soon as June 1 has galvanized lawmakers to intervene. But there is still no obvious way to reconcile Republican demands to slash federal spending with President Joe Biden’s demand to raise the debt ceiling and save the spending fight for a later date. Meanwhile, efforts to pass abortion bans in conservative states are starting to stall as some Republicans rebel against the most severe bans. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Alice Miranda Ollstein of Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Colorado Becomes the First State to Ban So-Called Abortion Pill Reversals
The controversial practice of administering progesterone to people after they have taken the abortion pill mifepristone may be coming to an end in Colorado. Pills have emerged as the latest front in the war over abortion since the U.S. Supreme Court overturned Roe v. Wade last summer.
After Idaho’s Strict Abortion Ban, OB-GYNs Stage a Quick Exodus
At least two Idaho hospitals are ending labor and delivery services, with one citing the state’s “legal and political climate” and noting that “recruiting replacements will be extraordinarily difficult” as doctors leave.
KFF Health News' 'What the Health?': Dancing Under the Debt Ceiling
House Republicans passed their plan to raise the nation’s debt ceiling, along with major cuts to health (and other domestic) programs. Unlikely to become law, it calls for new work requirements for adults on Medicaid. Meanwhile, state efforts targeting trans people bear a striking resemblance to the fight against abortion rights. Jessie Hellmann of CQ Roll Call, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Renuka Rayasam, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about a specialist’s demand to be paid as much as $15,000 before treating a woman’s serious pregnancy complication.
Listen: Mifepristone Remains Available for Now. What Happens Next?
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
Journalists Track Opioid Settlement Cash and Fees for Telehealth Visits
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
Watch: Rulings on Abortion Pill Have Far-Reaching Repercussions
Sarah Varney, a senior correspondent for KHN, joins Ali Rogin of PBS NewsHour to discuss the ruling by a federal judge in Texas that threatens nationwide access to the widely used abortion drug mifepristone, and a separate ruling in Washington state that reached the opposite conclusion.
Abortion Clinics in Conservative-Led States Face Increasing Legal Threats
Since the U.S. Supreme Court reversed federal protections for abortions, medical providers in conservative-led states have been fighting legal and political battles — as well as escalating threats from the anti-abortion movement.
As of April 1, states were allowed to begin reevaluating Medicaid eligibility for millions of Americans who qualified for the program during the covid-19 pandemic but may no longer meet the income or other requirements. As many as 15 million people could lose health coverage as a result. Meanwhile, the Medicare Hospital Insurance Trust Fund is projected to stay solvent until 2031, its trustees reported, taking some pressure off of lawmakers to finally fix that program’s underlying financial weaknesses. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Amy Goldstein of The Washington Post join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Daniel Chang, who reported the latest KHN-NPR “Bill of the Month” feature about a child not yet old enough for kindergarten whose medical bill landed him in collections.
Gov. Newsom Wanted California to Cut Ties With Walgreens. Then Federal Law Got in the Way.
Gov. Gavin Newsom declared that California would cut ties with Walgreens after the company said it would not distribute abortion pills in some states. But federal rules make it difficult for the state to unwind its Medicaid prescription drug agreement, which paid Walgreens $1.5 billion last year.
KFF Health News' 'What the Health?': A Judicial Body Blow to the ACA
A federal judge in Texas has dealt a big setback to the Affordable Care Act. The same judge who tried in 2018 to declare the entire ACA unconstitutional has now ruled that the law’s main provisions for preventive care are unconstitutional and, therefore, unenforceable nationwide. Also this week, North Carolina became the 40th state to expand Medicaid under the ACA. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sandhya Raman of CQ Roll Call join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.
KFF Health News' 'What the Health?': The Policy, and Politics, of Medicare Advantage
Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they’re leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent Julie Rovner to discuss these issues and more.
Judge Signals He Could Rule to Halt Sales of Common Abortion Pill
A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
KFF Health News' 'What the Health?': Judging the Abortion Pill
Any day now a conservative federal judge in Texas could upend the national abortion debate by requiring the FDA to rescind its approval of mifepristone, a drug approved in the U.S. more than 20 years ago that is now used in more than half of abortions nationwide. Meanwhile, a controversial study on masks gets a clarification, although it may be too late to change the public impression of what it found. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News' 'What the Health?': Biden Budget Touches All the Bases
Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the president’s policy priorities, and it’s clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR “Bill of the Month” features. Both were about families facing unexpected bills following childbirth.
Watch: Walgreens Won’t Sell Abortion Pill in 21 States Under GOP Threat of Legal Action
Under pressure from Republican attorneys general, the nation’s second-largest pharmacy chain says it will not dispense the abortion pill mifepristone.
